Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.

Safety Issues Clinical Trial

Official title:

An Evaluation of the Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Normal Blood Pressure in Normal, Healthy Individuals.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06442293
• Other study ID #: 202401CT
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2024
• Est. completion date: August 15, 2024

Study information

• Verified date: June 2024
• Source: USANA Health Sciences
• Contact: Mark Levy, PhD
• Phone: (801) 954-7783
• Email: mark.levy[@]usanainc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and tolerability of two distinct dietary supplement beverage formulations designed to maintain normal blood pressure. In this study, safety and tolerability will be assessed among otherwise healthy, normotensive individuals.

Description:

The objective of this study is to evaluate the safety of 2 dietary supplement beverage formulations in healthy, normotensive individuals. The study period will be 29 days in length, during which we will monitor and catalogue the blood pressure (BP), heart rate (HR), comprehensive metabolic panel (CMP), complete blood count (CBC), as well as self-reported side effects of all subjects on a daily basis. Note that each beverage will be evaluated at multiple doses: Beverage 1 will be monitored at a low, medium and high dose, where the medium and high dose is quantitatively twice (2X) and thrice (3X) the low dose (1X), respectively. Similarly, we will evaluate Beverage 2 at a low dose and high dose where the high dose is quantitatively twice (2X) of the low dose (1X). A placebo treatment will also be incorporated into this study as well. As such, there will be 6 groups in this study. Three subjects will be assigned to each treatment group for a total of 18 subjects.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 18
• Est. completion date: August 15, 2024
• Est. primary completion date: August 15, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• You are male or female between the ages of 18 and 50 (inclusive)

• You are in generally good health and taking no medications known to treat or affect blood pressure (e.g., angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, diuretics)

• You have a Body Mass Index of 18.5 to 30.0

• You have a resting blood pressure of systolic blood pressure (SBP) of 90 - 120 mm Hg and a diastolic blood pressure (DBP) 60 - 80 mm Hg

• You are comfortable reading and speaking in English

• You are fully able and willing to comply with the requirements of the study

• You are fully able and willing to keep scheduled appointments

• You have no known food allergies or intolerances

• Female individuals will be asked to complete a pregnancy screening test.

Exclusion Criteria:

• You are pregnant, attempting to become pregnant, or are currently lactating

• You currently use prescription or over-the-counter medications that may interfere with absorption of the test supplement or confound results (e.g., thiazide and loop diuretics for hypertension, corticosteroids)

• You have clinically important gastrointestinal, renal, hepatic, cardiac, pulmonary, pancreatic, neurologic or biliary disorders or conditions. Individuals with type 1 or type 2 diabetes will be excluded from the study

• You have illnesses or other medical conditions that will prevent or interfere with giving an informed consent, or with participation in the study.

• You have scheduling difficulties or lack of transportation that will prevent or interfere with their ability to attend all the necessary study visits.

• You have participated as a subject in any other clinical study within 30 days of the screening visit.

• You have a history of alcohol abuse or other substance abuse within the previous 2 years.

• You are currently using tobacco products including chewing tobacco and cigarettes.

Related Conditions & MeSH terms

• Safety Issues
• Tolerance

Intervention

Dietary Supplement:
• Treatment 1
A dietary supplement containing beet root extract, arginine and citrulline
• Treatment 2
A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract
• Placebo
a placebo supplement that is similar in appearance to treatment 1

Locations

Country	Name	City	State
United States	USANA Health Sciences	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
USANA Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Aggregate Adverse Symptom Score	An assessment of adverse symptoms categorized as either respiratory, cardiovascular, neurological or gastrointestinal. If symptoms present, they are rated on a scale from 1 to 10, with indicating very mild symptoms and 10 indicating very severe symptoms.	4 weeks
Secondary	Blood pressure assessment	An assessment of subjects' blood pressure throughout the 4-week study period.	4 weeks
Secondary	Heart rate monitoring	An assessment of subjects' heart rate throughout the 4-week study period.	4 weeks